Leadman(SZ:300289) 智通财经网·2025-11-13 11:37Core Viewpoint - Lideman (300289.SZ) is acquiring 70% of Xiansheng Xiangrui's shares for a total price of 1.733 billion yuan, aiming to enter the high-barrier bioproducts industry and enhance growth opportunities [1] Group 1: Acquisition Details - The acquisition involves cash payment to Shanghai Baijiahui Investment Management Co., Nanjing Baijiarui Enterprise Management Consulting Partnership, and Hainan Xiansheng Baijiahui Technology Development Co. for a total of 1.733 billion yuan [1] - Xiansheng Xiangrui primarily engages in the R&D, production, and sales of bioproducts, including in vitro diagnostic reagents and vaccines, focusing on tuberculosis screening and diagnosis [1] Group 2: Strategic Implications - By acquiring a controlling stake in Xiansheng Xiangrui, the company can quickly penetrate the bioproducts industry, significantly reducing the time and risk associated with developing new products and establishing market channels [1] - The acquisition allows the company to achieve a business transformation, forming a dual main business model of "bioproducts + in vitro diagnostics," driving growth through both independent R&D and external collaboration [1] - This strategic move is expected to create favorable conditions for enhancing the company's growth potential and providing better returns to investors [1]